Issue Date: January 11, 2016 | Web Date: January 7, 2016
FDA Issued Warning Letter to Cadila Healthcare
Cadila Healthcare, a major Indian generic drug company, has become the latest pharmaceutical manufacturer with a plant in India to be issued a U.S. FDA warning letter for failing to meet the regulatory standards of the U.S.
Warning letters are issued to firms that, during an inspection by FDA officials, are found to breach pharmaceutical manufacturing regulations. Recipients of the letters are often, but not always, banned in the U.S. from selling finished drugs and . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society